Adial to Present at Oppenheimer Conference; Phase 3 ONWARD Shows Promise
Adial Pharmaceuticals CEO Cary Claiborne will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 2:40 p.m. ET via live webcast. Its AD04 Phase 3 ONWARD trial demonstrated promising reductions in heavy drinking with no safety or tolerability concerns.
1. Conference Presentation Details
Cary Claiborne, CEO of Adial Pharmaceuticals, will deliver a presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 2:40 p.m. ET. The session will cover the company’s clinical progress and strategic initiatives.
2. Live Webcast and Investor Meetings
The presentation will be broadcast live via webcast with a replay available on the company’s investor relations website. Adial management has also scheduled one-on-one meetings with approved investors throughout the conference to discuss pipeline updates.
3. AD04 Phase 3 ONWARD Trial Results
Adial’s lead investigational product, AD04, is a genetically targeted serotonin-3 receptor antagonist undergoing a pivotal Phase 3 trial for Alcohol Use Disorder. The ONWARD trial showed promising reductions in heavy drinking among patients with specific genotypes and reported no overt safety or tolerability concerns.
4. Pipeline Expansion and Future Prospects
Beyond AUD, AD04 is being explored for treatment of opioid use disorder, gambling disorder, and obesity, leveraging the company’s companion diagnostic approach to target therapies based on genetic profiles.